Hologic, Inc. (HOLX) Shares Sold by Greenwood Capital Associates LLC
Greenwood Capital Associates LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 35.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,601 shares of the medical equipment provider’s stock after selling 4,809 shares during the period. Greenwood Capital Associates LLC’s holdings in Hologic were worth $390,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently modified their holdings of the company. Keybank National Association OH raised its position in Hologic by 44.8% in the second quarter. Keybank National Association OH now owns 36,771 shares of the medical equipment provider’s stock worth $1,669,000 after buying an additional 11,372 shares during the last quarter. Ray Gerald L & Associates Ltd. raised its position in Hologic by 2.5% in the second quarter. Ray Gerald L & Associates Ltd. now owns 16,350 shares of the medical equipment provider’s stock worth $742,000 after buying an additional 400 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new position in Hologic during the second quarter worth $2,278,000. Cambridge Investment Research Advisors Inc. bought a new position in Hologic during the second quarter worth $213,000. Finally, Neuberger Berman Group LLC raised its position in Hologic by 35.7% in the second quarter. Neuberger Berman Group LLC now owns 393,503 shares of the medical equipment provider’s stock worth $17,857,000 after buying an additional 103,629 shares during the last quarter. Institutional investors own 96.36% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ HOLX) opened at 37.92 on Thursday. The stock’s 50 day moving average price is $41.66 and its 200-day moving average price is $42.74. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The firm has a market capitalization of $10.64 billion, a PE ratio of 14.12 and a beta of 0.90.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same period in the previous year, the firm earned $0.51 EPS. Hologic’s revenue was up 12.4% on a year-over-year basis. Equities research analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/hologic-inc-holx-shares-sold-by-greenwood-capital-associates-llc/1534032.html.
A number of research firms have weighed in on HOLX. Jefferies Group LLC reiterated a “buy” rating and set a $49.00 price objective on shares of Hologic in a research note on Wednesday, June 28th. Barclays PLC reiterated an “overweight” rating and set a $53.00 price objective (up previously from $50.00) on shares of Hologic in a research note on Monday, July 17th. BidaskClub lowered Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Finally, Bank of America Corporation reiterated a “neutral” rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a research note on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.64.
In related news, VP Karleen Marie Oberton sold 4,704 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the sale, the director now owns 23,810 shares in the company, valued at $955,257.20. The disclosure for this sale can be found here. Insiders sold a total of 32,353 shares of company stock worth $1,415,186 over the last quarter. Insiders own 0.79% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.